Obesity

Expanding weightloss drug doesn't wow

An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.

Dr. Oz runs afoul of lawmakers

Lawmakers criticized Columbia University chairman and professor of surgery Dr. Mehmet Oz for calling weight-loss supplements miracles on his TV program, despite lacking scientific proof to support those claims.

OPDP says phentermine site thin on details

OPDP says phentermine site thin on details

By

The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.

FDA pauses Orexigen drug approval

FDA pauses Orexigen drug approval

By

The regulator wants more time to discuss post-marketing requirements.

Obesity cause of knee replacement increase

A study shows that total knee replacement is rising—and occurring in more youthful people. The uptick tracks with the rise in obesity.

Two more obesity meds circle Rx status

Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.

Weight-loss drugs fight it out

Eisai announced it was adding sales reps to promote its drug Belviq, while Vivus, maker of Qsymia, fights off a generic marketing application by Actavis.

Belviq partners up with phentermine

Arena and Eisai are testing Belviq with appetite suppressant phentermine.

Tot obesity drops, market ceiling still high

Tot obesity drops, market ceiling still high

By

A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.

Weight-loss drugs plateau and expand

Weight-loss drugs plateau and expand

By

Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.

Merck's obesity intervention

The drugmaker's new subsidiary will provide behavior and activity training, among other services.

Orexigen files weight-loss NDA

Orexigen files weight-loss NDA

By

The company expects to join the prescription weight-loss market by 2014's third quarter.

Orexigen could enter weight-loss race June 2014

Orexigen could enter weight-loss race June 2014

By

The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.

Vivus slims down in wake of sluggish sales

Vivus slims down in wake of sluggish sales

By

The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.

Molecule uses hormones to fight diabetes

Researchers think a two-hormone approach could help control diabetes and obesity.

Eisai fills out Belviq consumer outreach

Eisai fills out Belviq consumer outreach

By

The marketing push follows the September launch of a patient support program and the announcement it was doubling its sales force.

Eisai to increase Belviq sales force

Eisai to increase Belviq sales force

By

Eisai, the marketing half of the Arena-Eisai collaboration, plans to double the sales force by December.

Analyst: Eisai should hire more Belviq reps

Analyst: Eisai should hire more Belviq reps

By

A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.

Vivus pins Qsymia hopes on J&J vet after Zook steps down

Vivus pins Qsymia hopes on J&J vet after Zook steps down

By

J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec's appointment.

CDC finds the sleepless and educated use Rx aids

CDC finds the sleepless and educated use Rx aids

By

The Centers for Disease Control and Prevention profiles the typical sleep aid user, and finds that eight hours does not mean consumers are sleeping without help.

Business briefs: Bristol-Myers Squibb, Zafgen, GSK, Shire

Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration

Business briefs: Eisai, AHRQ, mWellnesss

Eisai uses a lawsuit to prompt the DEA, AHRQ gets a new director, mWellness runs into adherence issues.

Business briefs: Eisai, Merck, plus another ACA delay

Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back

Business briefs: GSK, Vivus, Biogen Idec, Astellas, Myriad

GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues

Obesity marketing to stay same, despite new AMA designation

Obesity marketing to stay same, despite new AMA designation

By

Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.

Novo, Deen agree to suspend their relationship

Novo, Deen agree to suspend their relationship

By

Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.

Business briefs: Alexion, AMA, Eli Lilly

Alexion plans on moving into new HQ in 2015, AMA declares obesity is a disease, FDA looks into Zyprexa patient deaths

Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN

Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site

Weight-loss category expands by one

By

Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.

Business briefs: AbbVie, AstraZeneca, Valeant, Merck, Novo Nordisk

AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight loss results.

Email Newsletters